p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2

Cell

Volumn 128, Issue 2, 2007, Pages 281-294

  Chu, Isabel ^a,b   Sun, Jun ^a   Arnaout, Angel ^b   Kahn, Harriette ^c   Hanna, Wedad ^c   Narod, Steven ^c   Sun, Ping ^c   Tan, Cheng Keat ^a   Hengst, Ludger ^d   Slingerland, Joyce ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 0530; CYCLIN DEPENDENT KINASE 2; CYCLIN E; PROTEIN P27; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CANADA; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL MEMBRANE STEADY POTENTIAL; CELL STRAIN MCF 7; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; STEADY STATE; TISSUE MICROARRAY;

EID: 33846268807     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2006.11.049     Document Type: Article

References (64)

1. Agrawal D., Hauser P., McPherson F., Dong F., Garcia A., and Pledger W.J. Repression of p27kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. Mol. Cell. Biol. 16 (1996) 4327-4336
2. Alkarain A., Jordan R., and Slingerland J. p27 deregulation in breast cancer: prognostic significance and implications for therapy. J. Mammary Gland Biol. Neoplasia 9 (2004) 67-80
3. Belsches-Jablonski A.P., Biscardi J.S., Peavy D.R., Tice D.A., Romney D.A., and Parsons S.J. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20 (2001) 1465-1475
4. Benz C.C., Scott G.K., Sarup J.C., Johnson R.M., Tripathy D., Coronado E., Shepard H.M., and Osborne C.K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24 (1992) 85-95
5. Besson A., Gurian-West M., Chen X., Kelly-Spratt K.S., Kemp C.J., and Roberts J.M. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev. 20 (2006) 47-64
6. Biscardi J.S., Maa M.C., Tice D.A., Cox M.E., Leu T.H., and Parsons S.J. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem. 274 (1999) 8335-8343
7. Biscardi J.S., Ishizawar R.C., Silva C.M., and Parsons S.J. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2 (2000) 203-210
8. Cariou S., Donovan J.C., Flanagan W.M., Milic A., Bhattacharya N., and Slingerland J.M. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. USA 97 (2000) 9042-9046
9. Carrano A.C., Eytan E., Hershko A., and Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1 (1999) 193-199
10. Catzavelos C., Bhattacharya N., Ung Y.C., Wilson J.A., Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L., et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 3 (1997) 227-230
11. Chen T., George J.A., and Taylor C.C. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?. Anticancer Drugs 17 (2006) 123-131
12. Chu I., Blackwell K., Chen S., and Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 65 (2005) 18-25
13. Ciarallo S., Subramaniam V., Hung W., Lee J.H., Kotchetkov R., Sandhu C., Milic A., and Slingerland J.M. Altered p27(Kip1) phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor beta-mediated G(1) arrest. Mol. Cell. Biol. 22 (2002) 2993-3002
14. Connor M.K., Kotchetkov R., Cariou S., Resch A., Lupetti R., Beniston R.G., Melchior F., Hengst L., and Slingerland J.M. CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol. Biol. Cell 14 (2003) 201-213
15. Donovan J.C., Milic A., and Slingerland J.M. Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J. Biol. Chem. 276 (2001) 40888-40895
16. Egan C., Pang A., Durda D., Cheng H.C., Wang J.H., and Fujita D.J. Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene 18 (1999) 1227-1237
17. Fero M.L., Rivkin M., Tasch M., Porter P., Carow C.E., Polyak K., Firpo E., Tsai L., Broudy V., Perlmutter R.M., et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis and female sterility in p27Kip1-deficient mice. Cell 85 (1996) 733-744
18. Fero M.L., Randel E., Gurley K.E., Roberts J.M., and Kemp C.J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396 (1998) 177-180
19. Florenes V.A., Bhattacharya N., Bani M.R., Ben-David Y., Kerbel R.S., and Slingerland J.M. TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1. Oncogene 13 (1996) 2447-2457
20. Frame M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta 1602 (2002) 114-130
21. Gonzalez L., Agullo-Ortuno M.T., Garcia-Martinez J.M., Calcabrini A., Gamallo C., Palacios J., Aranda A., and Martin-Perez J. Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J. Biol. Chem. 281 (2006) 20851-20864
22. Gopfert U., Kullmann M., and Hengst L. Cell cycle-dependent translation of p27 involves a responsive element in its 5′-UTR that overlaps with a uORF. Hum. Mol. Genet. 12 (2003) 1767-1779
23. Grimmler M., Wang Y., Mund T., Cilensek Z., Keidel E.-M., Waddell M.B., Jäkel H., Kullmann M., Kriwacki R.W., and Hengst L. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 128 (2007) 269-280 this issue
24. Hara T., Kamura T., Nakayama K., Oshikawa K., Hatakeyama S., and Nakayama K.I. Degradation of p27Kip1 at the G0-G1 transition mediated by a Skp2-independent ubiquitination pathway. J. Biol. Chem. 276 (2001) 48937-48943
25. Hara T., Kamura T., Kotoshiba S., Takahashi H., Fujiwara K., Onoyama I., Shirakawa M., Mizushima N., and Nakayama K.I. Role of the UBL-UBA protein KPC2 in degradation of p27 at G1 phase of the cell cycle. Mol. Cell. Biol. 25 (2005) 9292-9303
26. Hengst L., and Reed S.I. Translational control of p27Kip1 accumulation during the cell cycle. Science 271 (1996) 1861-1864
27. Hengst L., Dulic V., Slingerland J.M., Lees E., and Reed S.I. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA 91 (1994) 5291-5295
28. Hiscox S., Morgan L., Green T.P., Barrow D., Gee J., and Nicholson R.I. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat. 97 (2005) 263-274 10.1007/s10549-005-9120-9 Published online December 7, 2005
29. Irby R.B., and Yeatman T.J. Role of Src expression and activation in human cancer. Oncogene 19 (2000) 5636-5642
30. Irby R.B., Mao W.G., Coppola D., Kang J., Loubeau J.M., Trudeau W., Karl R., Fujita D.J., Jove R., and Yeatman T.J. Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. 21 (1999) 187-190
31. Kip 1 on serine 10 is required for its binding to CRM1 and nuclear export. J. Biol. Chem. 277 (2002) 14355-14358
32. Ishizawar R., and Parsons S.J. c-Src and cooperating partners in human cancer. Cancer Cell 6 (2004) 209-214
33. Johnson D., Frame M.C., and Wyke J.A. Expression of the v-Src oncoprotein in fibroblasts disrupts normal regulation of the CDK inhibitor p27 and inhibits quiescence. Oncogene 16 (1998) 2017-2028
34. Kamura T., Hara T., Matsumoto M., Ishida N., Okumura F., Hatakeyama S., Yoshida M., Nakayama K., and Nakayama K.I. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat. Cell Biol. 6 (2004) 1229-1235
35. Kardinal C., Dangers M., Kardinal A., Koch A., Brandt D.T., Tamura T., and Welte K. Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27Kip1 in the acute promyelocytic leukemia cell line NB4. Blood 107 (2006) 1133-1140
36. Kiyokawa H., Kineman R.D., Manova-Todorova K.O., Soares V.C., Hoffman E.S., Ono M., Khanam D., Hayday A.C., Frohman L.A., and Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85 (1996) 721-732
37. Koff A., Ohtsuki M., Polyak K., Roberts J.M., and Massague J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science 260 (1993) 536-539
38. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S., Torhorst J., Mihatsch M.J., Sauter G., and Kallioniemi O.P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. 1. Nat. Med. 4 (1998) 844-847
39. Lane H.A., Beuvink I., Motoyama A.B., Daly J.M., Neve R.M., and Hynes N.E. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol. 20 (2000) 3210-3223
40. Lenferink A.E.G., Simpson J.F., Shawver L.K., Coffey R.J., Forbes J.T., and Arteaga C.L. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu plus MMTV/TGF-alpha bigenic mice. Proc. Natl. Acad. Sci. USA 97 (2000) 9609-9614
41. Liang J., and Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2 (2003) 339-345
42. Malek N.P., Sundberg H., McGrew S., Nakayama K., Kyriakidis T.R., and Roberts J.M. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature 413 (2001) 323-327
43. Migliaccio A., DiDomenico M., Castona C., DeFalco A., Bontempo P., Nola E., and Auricchio F. Tyrosine kinas/p21ras/MAP-kinase pathway activation by estradiol receptor complex in MCF-7 cells. EMBO J. 15 (1996) 1292-1300
44. Montagnoli A., Fiore F., Eytan E., Carrano A.C., Draetta G.F., Hershko A., and Pagano M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 13 (1999) 1181-1189
45. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., and Loh D.Y. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85 (1996) 707-720
46. Nicholson S., Wright C., Sainsbury J.R., Halcrow P., Kelly P., Angus B., Farndon J.R., and Harris A.L. Epidermal growth factor receptor (EGFR) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J. Steroid Biochem. Mol. Biol. 37 (1990) 811-814
47. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., Yew P.R., Draetta G.F., and Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269 (1995) 682-685
48. Pietras R.J., Arboleda J., Reese D.M., Wongvipat N., Pegram M.D., Ramos L., Gorman C.M., Parker M.G., Sliwkowski M.X., and Slamon D.J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 (1995) 2435-2446
49. Ple P.A., Green T.P., Hennequin L.F., Curwen J., Fennell M., Allen J., Lambert-Van Der Brempt C., and Costello G. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. 1. J. Med. Chem. 47 (2004) 871-887
50. Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massague J., Roberts J.M., and Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8 (1994) 9-22
51. Radeva G., Petrocelli T., Behrend E., Leung-Hagesteijn C., Filmus J., Slingerland J., and Dedhar S. Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J. Biol. Chem. 272 (1997) 13937-13944
52. Riley D., Carragher N.O., Frame M.C., and Wyke J.A. The mechanism of cell cycle regulation by v-Src. Oncogene 20 (2001) 5941-5950
53. Rodier G., Montagnoli A., Di Marcotullio L., Coulombe P., Draetta G.F., Pagano M., and Meloche S. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 20 (2001) 6672-6682
54. Russo A.A., Jeffrey P.D., Patten A.K., Massague J., and Pavletich N.P. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382 (1996) 325-331
55. Sheaff R.J., Groudine M., Gordon M., Roberts J.M., and Clurman B.E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 11 (1997) 1464-1478
56. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
57. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
58. Slingerland J.M., Hengst L., Pan C.H., Alexander D., Stampfer M.R., and Reed S.I. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol. Cell. Biol. 14 (1994) 3683-3694
59. Song R.X., Barnes C.J., Zhang Z.G., Bao Y.D., Kumar R., and Santen R.J. The role of Shc and insulin-like qrowth factor 1 receptor in mediating the translocation of estrogen receptor a to the plasma membrane. Proc. Natl. Acad. Sci. USA 101 (2004) 2076-2081
60. Thomas S.M., and Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13 (1997) 513-609
61. Tice D.A., Biscardi J.S., Nickles A.L., and Parsons S.J. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA 96 (1999) 1415-1420
62. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., and Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res. Treat. 71 (2002) 67-75
63. Vlach J., Hennecke S., and Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 16 (1997) 5334-5344
64. Yang H.Y., Zhou B.P., Hung M.C., and Lee M.H. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J. Biol. Chem. 275 (2000) 24735-24739